Clinical Trials Browser

Terminated × OTHER_GOV × Everolimus × Clear all

NCT01939418 2017-10-03

Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01412515 2012-01-02

A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma

Phase 2 Terminated

Sarcoma, Kaposi